Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra + IVIG vs IVIG alone in IVIG-refractory Kawasaki disease
jRCT2031240646Recruiting
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of anakinra in Kawasaki disease (KD) (2 arms). Primary endpoint: Antipyretic rate within 48 hours after administration of the investigational product. Started Jan 2025; status: recruiting.
02
Drugs
anakinra
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on jRCT2031240646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240646.